FDA OKs Cough Medicine of Perrigo, Actavis

Actavis plc and its partner Perrigo Company plc have announced that Actavis has received US Food and Drug Administration approval for their abbreviated new drug application (ANDA) for guaifenesin/pseudoephedrine tablets and that Perrigo will begin shipments in time for the cough/cold season to its retail and wholesale customers in the US. The product will be packaged and marketed under store and proprietary brands and will be an alternative to Mucinex D tablets. Mucinex D (guaifenesin/pseudoephedrine tablets), an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of approximately $83 million through food, drug and mass merchandisers over the last 12 months, according to information from Actavis.

Source: Actavis

Leave a Reply

Your email address will not be published. Required fields are marked *